NCT04403087

Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications

Additive Effect of Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications; an Open-label, Randomized Controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 132 (actual)
• Sponsor: Chuncheon Sacred Heart Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Adverse events related to the eradication medication is one of the reason of lower eradication success in the H. pylori treatment. The aim of this study was to evaluate the additive effect of trimebutine for the development of adverse events related to the H. pylori eradication regimen.

Detailed description

Adverse events related to the eradication medication is one of the reason of lower eradication success in the H. pylori treatment. The common adverse events related to the eradication medications area as follows; Abdomen discomfort, pain, nausea, vomiting, diarrhea, bloating, urticaria, dizziness, headache, etc,. Various methods have been tried to reduce or prevent the adverse events related to the eradication medications. However, there is no established methods to reduce or prevent these events. The aim of this study was to evaluate the additive effect of trimebutine for the development of adverse events related to the H. pylori eradication regimen.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Trimebutine 100 MG	Trimebutine 100mg three times a day

Timeline

• Start date: 2021-05-01
• Primary completion: 2021-06-01
• Completion: 2021-07-01
• First posted: 2020-05-27
• Last updated: 2022-07-12

Locations

1 site across 1 country: South Korea